![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Rapid Therapeutic Science Laboratories Inc (PK) | USOTC:RTSL | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.004 | 0.004 | 0.0077 | 0.00 | 14:30:17 |
RAPID THERAPEUTIC SCIENCE LABORATORIES, INC.
558 County Road 472
De Leon, Texas 76444
May 16, 2023
VIA Edgar
Division of Corporation Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re:Rapid Therapeutic Science Laboratories, Inc.
Form S-1 Registration Statement
File No. 333-255022
Ladies and Gentlemen:
Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the Company’s Registration Statement on Form S-1 originally filed with the Securities and Exchange Commission on April 5, 2021 (File No. 333-255022), and all amendments filed thereto, if any, and all exhibits filed therewith (the “Registration Statement”), be withdrawn effective immediately pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities Act”). The Company is requesting the withdrawal of the Registration Statement because the Company no longer intends to proceed with the offering contemplated therein at this time. The Registration Statement was never declared effective and no securities of the Company were sold in connection with the offering.
The Company also requests in accordance with Rule 457(p) of the Securities Act that all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use.
Any questions or comments regarding this letter should be directed to the Company’s Chief Executive Officer, Donal R. Schmidt, Jr., at (800) 497-6059.
Thank you for your assistance in this matter.
Sincerely,
/s/ Donal R. Schmidt, Jr.
Donal R. Schmidt, Jr.
Chief Executive Officer
1 Year Rapid Therapeutic Scienc... (PK) Chart |
1 Month Rapid Therapeutic Scienc... (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions